Artelo Biosciences (ARTL) Change in Account Payables (2016 - 2025)
Artelo Biosciences (ARTL) posted quarterly Change in Account Payables of $312000.0 for Q4 2025, up 1100.0% year-over-year from $26000.0 in Q4 2024, and up 4357.14% quarter-over-quarter from $7000.0 in Q3 2025.
Artelo Biosciences (ARTL) Change in Account Payables (2016 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Change in Account Payables for 8 consecutive years, with $312000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Account Payables rose 1100.0% year-over-year to $312000.0; the TTM figure through Dec 2025 stood at $283000.0 (up 812.9% YoY), while the FY2025 annual figure was $283000.0, up 812.9% from the prior year.
- Change in Account Payables improved to $312000.0 in Q4 2025 per ARTL's latest filing, from $7000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $312000.0 in Q4 2025 and bottomed at -$43000.0 in Q2 2023.
- Historically, Change in Account Payables has averaged $19705.9 across 5 years, with a median of $6000.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Account Payables slumped 816.67% — and 2025, when it surged 1100.0%.
- Artelo Biosciences' Change in Account Payables stood at $11000.0 in 2021, then soared by 145.45% to $27000.0 in 2022, then plunged by 166.67% to -$18000.0 in 2023, then soared by 244.44% to $26000.0 in 2024, then soared by 1100.0% to $312000.0 in 2025.
- Business Quant data shows ARTL's Change in Account Payables at $312000.0 in Q4 2025, $7000.0 in Q3 2025, and $2000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | 312,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 312,000.00 |
| Dec 31, 2025 | 312,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Mar 31, 2025 | -38,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Dec 31, 2024 | 26,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Jun 30, 2024 | -39,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Dec 31, 2023 | -18,000.00 |
| Dec 31, 2023 | -18,000.00 |
| Sep 30, 2023 | 4,000.00 |
| Sep 30, 2023 | 4,000.00 |